keyword
MENU ▼
Read by QxMD icon Read
search

Ptcl

keyword
https://www.readbyqxmd.com/read/28426230/photophysics-and-excited-state-properties-of-cyclometalated-iridium-iii-platinum-ii-and-iridium-iii-iridium-iii-bimetallic-complexes-bridged-by-dipyridylpyrazine
#1
Yang-Jin Cho, So-Yoen Kim, Chang Min Choi, Nam Joon Kim, Chul Hoon Kim, Dae Won Cho, Ho-Jin Son, Chyongjin Pac, Sang Ook Kang
We investigated the electrochemical and excited-state properties of 2,3-bis(2-pyridyl)pyrazine (dpp)-bridged bimetallic complexes, (L)2Ir-dpp-PtCl [1, L = 2-(4',6'-difluorophenyl)pyridinato-N,C(2) (dfppy); 2, L = 2-phenylpyridinato-N,C(2) (ppy)] and [(L)2Ir]2(dpp) [3, L = dfppy; 4, L = ppy] compared to monometallic complexes, (L)2Ir-dpp (5, L = dfppy; 6, L = ppy) and dpp-PtCl (dpp-Pt(II)Cl2; 7). The single-crystal X-ray crystallographic structures of 1, 3, 5, and 6 showed that 1 and 3 have approximately coplanar structures of the dpp unit, while the noncoordinated pyridine ring of dpp in 5 and 6 is largely twisted with respect to the pyrazine ring...
April 20, 2017: Inorganic Chemistry
https://www.readbyqxmd.com/read/28420721/phase-i-study-of-fenretinide-delivered-intravenously-in-patients-with-relapsed-or-refractory-hematologic-malignancies-a-california-cancer-consortium-trial
#2
Ann Mohrbacher, Allen S Yang, Susan Groshen, Shivaani Kummar, Martin E Gutierrez, Min H Kang, Denice Tsao-Wei, C Patrick Reynolds, Edward Newman, Barry J Maurer
A phase I study was conducted to determine the maximum-tolerated dose (MTD), dose-limiting toxicities (DLT), and pharmacokinetics of fenretinide delivered as an intravenous emulsion in relapsed/refractory hematologic malignancies. <br /><br />Experimental Design: Fenretinide (80 - 1810 mg/m(2)/day) was administered by continuous infusion on Days 1 - 5, in 21-day cycles, using an accelerated titration design. <br /><br />Results: Twenty-nine patients, treated with a median of three prior regimens (range, 1 to 7), were enrolled and received test drug...
April 18, 2017: Clinical Cancer Research: An Official Journal of the American Association for Cancer Research
https://www.readbyqxmd.com/read/28412739/retinoic-acid-receptor-alpha-drives-cell-cycle-progression-and-is-associated-with-increased-sensitivity-to-retinoids-in-t-cell-lymphoma
#3
Xueju Wang, Surendra Dasari, Grzegorz S Nowakowski, Konstantinos N Lazaridis, Eric D Wieben, Marshall E Kadin, Andrew L Feldman, Rebecca L Boddicker
Peripheral T-cell lymphomas (PTCLs) are aggressive non-Hodgkin lymphomas with generally poor outcomes following standard therapy. Few candidate therapeutic targets have been identified to date. Retinoic acid receptor alpha (RARA) is a transcription factor that modulates cell growth and differentiation in response to retinoids. While retinoids have been used to treat some cutaneous T-cell lymphomas (CTCLs), their mechanism of action and the role of RARA in CTCL and other mature T-cell lymphomas remain poorly understood...
February 17, 2017: Oncotarget
https://www.readbyqxmd.com/read/28387513/heteroleptic-cycloplatinated-n-heterocyclic-carbene-complexes-a-new-approach-to-highly-efficient-blue-light-emitters
#4
Sara Fuertes, Andrés J Chueca, Lorenzo Arnal, Antonio Martín, Umberto Giovanella, Chiara Botta, Violeta Sicilia
New heteroleptic compounds of platinum(II)-containing cyclometalated N-heterocyclic carbenes, [PtCl(R-C^C*)(PPh3)] [R-CH^C*-κC* = 3-methyl-1-(naphthalen-2-yl)-1H-imidazol-2-ylidene (R-C = Naph; 1A), 1-[4-(ethoxycarbonyl)phenyl]-3-methyl-1H-imidazol-2-ylidene (R = CO2Et; 1B), and [Pt(R-C^C*)(py)(PPh3)]PF6 (py = pyridine; R-C = Naph, 2A; R = CO2Et, 2B], have been prepared and fully characterized. All of them were obtained as the trans-(C*,PPh3) isomer in high yields. The selectivity of their synthesis has been explained in terms of the degree of transphobia (T) of pairs of ligands in trans positions...
April 7, 2017: Inorganic Chemistry
https://www.readbyqxmd.com/read/28382854/lymphoma-classification-in-goats
#5
Patti K Kiser, Christiane V Löhr
Lymphoma has been described in individual cases for goats but not systematically characterized in a larger cohort. This study aimed to subtype caprine lymphoma based on topographic and subgross distribution, immunophenotype, and cellular morphology following the World Health Organization classification system for hematopoietic tumors in domestic animals. Fifteen caprine lymphoma cases were assessed with 6 submitted as biopsy and 9 for postmortem examination. Goats were predominantly young adult (median 3 years) and dwarf breeds (Pygmy and Pygora)...
January 1, 2017: Veterinary Pathology
https://www.readbyqxmd.com/read/28375859/primary-cutaneous-follicular-helper-t-cell-lymphoma-a-case-series-and-review-of-the-literature
#6
James Y Wang, Giang Huong Nguyen, Jia Ruan, Cynthia M Magro
Primary cutaneous follicular helper T-cell (Tfh) lymphoma is a recently described variant of peripheral T-cell lymphoma-not otherwise specified. This particular variant, usually presenting as a sudden onset of multiple plaques and nodules, is characterized by tumoral atypical T cells that express an array of Tfh markers, such as inducible T-cell costimulator, Bcl-6, CXCL13, PD-1, and CD10. The authors now present 3 patients whose known clinical skin findings are consistent with PTCL of Tfh origin (PTCL-Tfh)...
May 2017: American Journal of Dermatopathology
https://www.readbyqxmd.com/read/28340883/novel-agents-in-the-treatment-of-relapsed-or-refractory-peripheral-t-cell-lymphoma
#7
REVIEW
Enrica Marchi, Alexander G Raufi, Owen A O'Connor
Peripheral T-cell lymphomas (PTCL) are a heterogeneous group of mature T-cell malignancies associated with exceptionally poor prognoses. Currently, chemotherapy remains the standard of care, but outcomes are suboptimal, with 5-year survival rates ranging from 15% to 25%. In recent years, several novel agents, including pralatrexate, romidepsin, belinostat, and brentuximab vedotin, have been approved for the treatment of relapsed/refractory PTCL. In addition, numerous other therapies with different mechanisms of action and targets are currently under investigation...
April 2017: Hematology/oncology Clinics of North America
https://www.readbyqxmd.com/read/28340873/peripheral-t-cell-lymphoma-not-otherwise-specified-a-review-of-current-disease-understanding-and-therapeutic-approaches
#8
REVIEW
Musa Al-Zahrani, Kerry J Savage
Peripheral T-cell lymphoma, not otherwise specified (PTCL-NOS), corresponds with a heterogeneous group of mature T-cell lymphomas. Recent gene expression profiling studies have identified at least two molecular subgroups (GATA3 and TBX2). Standard treatment and outcomes remain poor. High-dose chemotherapy with autologous stem cell transplantation is incorporated into primary therapy for young fit patients but remains ineffective for most and has not been tested in a randomized study. Several novel agents have been approved for use in relapsed/refractory PTCLs, and although response rates are modest for most, durable remissions have been reported...
April 2017: Hematology/oncology Clinics of North America
https://www.readbyqxmd.com/read/28329608/atypical-lymphoproliferative-disorder-clinical-and-pathological-features
#9
Kelly Wilmas, Madeleine Duvic, Yasuhiro Oki
Definitive diagnosis of cutaneous lymphoproliferative disorders is one of the most challenging issues in dermatopathology owing to the broad spectrum of clinical and histopathological presentations. We report a case of a 73-year-old woman who presented with a single, asymptomatic plaque limited to her left collarbone. This was followed by the appearance of several plaques and patches in addition to a tumor. Her initial biopsy suggested a CD4/CD8 double negative mycosis fungoides (MF). However, the rapidly progressive course of her disease is worrisome for peripheral T-cell lymphomas-not otherwise specified (PTCL-NOS)...
September 15, 2016: Dermatology Online Journal
https://www.readbyqxmd.com/read/28317459/outcome-of-peripheral-t-cell-lymphoma-in-first-complete-remission-a-danish-swedish-population-based-study
#10
Henrik Cederleuf, Lasse Hjort Jakobsen, Fredrik Ellin, Peter de Nully Brown, Thomas Stauffer Larsen, Martin Bøgsted, Thomas Relander, Mats Jerkeman, Tarec Christoffer El-Galaly
In the present study, we investigate the outcome of 109 Danish and 123 Swedish patients with nodal PTCL in first complete remission (CR), and examine the impact of imaging-based follow-up (FU) strategies. The patients were selected by the following criteria: (a) newly diagnosed nodal PTCL from 2007 to 2012, (b) age ≥18 years, and (c) CR after CHOP or CHOEP therapy. FU guidelines in Sweden included symptom assessment, clinical examinations and blood tests at 3-4-month intervals for 2 years. FU strategies in Denmark was similar but included routine imaging, usually every 6 months for 2 years...
March 20, 2017: Leukemia & Lymphoma
https://www.readbyqxmd.com/read/28306367/the-clinical-significance-of-epstein-barr-virus-dna-in-peripheral-blood-mononuclear-cells-in-patients-with-non-hodgkin-lymphoma
#11
Yi Chen, Xiaoyun Zheng, Buyuan Chen, Xiaozhu Yang, Jing Zheng, Zhihong Zheng, Ting Yang, Tingbo Liu, Jianda Hu
The aim of the study was to determine the clinical significance of EBV DNA in the peripheral blood mononuclear cells (PBMCs) from the patients with non-Hodgkin lymphoma (NHL). Newly diagnosed patients with NHL were enrolled in the study (n = 328), and clinical data retrospectively analyzed. EBV DNA was detectable in 34.8% of patients, and the positivity rate was 51.6% for T/NK cell subtype and 24.3% for B cell subtype (p < .001). In diffuse large B cell lymphoma (DLBCL), extranodal NK/T-cell lymphoma, nasal type (ENKTL), peripheral T-cell lymphoma not otherwise classified (PTCL...
March 17, 2017: Leukemia & Lymphoma
https://www.readbyqxmd.com/read/28303495/genetic-landscape-and-classification-of-peripheral-t-cell-lymphomas
#12
REVIEW
Rosalind F Sandell, Rebecca L Boddicker, Andrew L Feldman
PURPOSE OF REVIEW: Peripheral T cell lymphomas (PTCLs) are markedly heterogeneous at the clinical, pathological, and molecular levels. This review will discuss genetic findings in PTCL with special emphasis on how they impact lymphoma classification. RECENT FINDINGS: Sequencing studies have identified recurrent genetic alterations in nearly every PTCL subtype. In anaplastic large cell lymphoma, these studies have revealed novel chromosomal rearrangements and mutations that have prognostic significance and may suggest new therapeutic approaches...
April 2017: Current Oncology Reports
https://www.readbyqxmd.com/read/28290723/accuracy-of-18-f-fdg-pet-ct-to-detect-bone-marrow-clearance-in-patients-with-peripheral-t-cell-lymphoma-tissue-remains-the-issue
#13
Anthony Q Pham, Stephen M Broski, Thomas M Habermann, Dragan Jevremovic, Gregory A Wiseman, Andrew L Feldman, Matthew J Maurer, Kay M Ristow, Thomas E Witzig
Staging of peripheral T-cell non-Hodgkin lymphoma (PTCL) is determined by 18-F FDG PET scan and bone marrow biopsy. This study addressed the accuracy of PET at detecting bone marrow (BM) involvement at restaging in patients with known involvement pretreatment. We identified patients with biopsy proven BM PTCL at diagnosis and concomitant BM and PET at the end of therapy. Pre-treatment PET demonstrated 50% (8/16) had a false-negative PET scan of the BM. After induction, repeat biopsy revealed 62.5% (10/16) with BM involvement...
March 14, 2017: Leukemia & Lymphoma
https://www.readbyqxmd.com/read/28264616/romidepsin-is-effective-and-well-tolerated-in-older-patients-with-peripheral-t-cell-lymphoma-analysis-of-two-phase-ii-trials
#14
Andrei Shustov, Bertrand Coiffier, Steven Horwitz, Lubomir Sokol, Barbara Pro, Julie Wolfson, Barbara Balser, Robin Eisch, Leslie Popplewell, H Miles Prince, Steven L Allen, Richard Piekarz, Susan Bates
Peripheral T-cell lymphomas (PTCLs) are a rare group of lymphoid neoplasms with high relapse rates after initial therapy and poor prognosis. Most patients are aged ≥60 years and are often not candidates for aggressive salvage therapies. Romidepsin, a potent class I histone deacetylase inhibitor, has shown significant single-agent activity in relapsed/refractory PTCL. We evaluated the efficacy and tolerability of romidepsin in elderly patients in this setting. Ninety-five patients aged ≥60 years were identified from 2 prospective phase 2 registration trials of romidepsin, and comparative analyses were performed with younger patients from these trials...
March 7, 2017: Leukemia & Lymphoma
https://www.readbyqxmd.com/read/28222648/autologous-stem-cell-transplantation-as-frontline-strategy-for-peripheral-t-cell-lymphoma-a-single-centre-experience
#15
Xiao Han, Wei Zhang, Daobin Zhou, Jing Ruan, Minghui Duan, Tienan Zhu, Jian Li, Huacong Cai, Xinxin Cao, Mingqi Ouyang
Objective To determine the efficacy and prognosis of autologous hematopoietic stem cell transplantation (ASCT) as frontline treatment for peripheral T cell lymphoma (PTCL). Methods Clinical data from 46 PTCL patients who achieved complete (CR) or partial remission (PR) after ASCT from October 1996 to July 2014 were analysed retrospectively. Results Median patient age was 32 (range: 15-68) years. Disease types included PTCL, unspecified type, in 23 patients, anaplastic large cell lymphoma in eight, angioimmunoblastic lymphoma in eight, extranodal NK/T-cell lymphoma in five, and hepatosplenic T-cell lymphoma and enteropathy associated T-cell lymphoma in one each...
February 2017: Journal of International Medical Research
https://www.readbyqxmd.com/read/28218839/phosphenium-hydride-reduction-of-cod-mx2-m-pd-pt-x-cl-br-snapshots-on-the-way-to-phosphenium-metal-0-halides-and-synthesis-of-metal-nanoparticles
#16
Jan Nickolaus, Dominik A Imbrich, Simon H Schlindwein, Adrian H Geyer, Martin Nieger, Dietrich Gudat
The outcome of the reduction of [(cod)PtX2] (X = Cl, Br; cod = 1,5-cyclooctadiene) with N-heterocyclic phosphenium hydrides (R)NHP-H depends strongly on the steric demand of the N-aryl group R and the nature of X. Reaction of [(cod)PtCl2] with (Dipp)NHP-H featuring bulky N-Dipp groups produced an unprecedented monomeric phosphenium metal(0) halide [((Dipp)NHP)((Dipp)NHP-H)PtCl] stabilized by a single phosphine ligand. The phosphenium unit exhibits a pyramidal coordination geometry at the phosphorus atom and may according to DFT calculations be classified as a Z-type ligand...
February 20, 2017: Inorganic Chemistry
https://www.readbyqxmd.com/read/28210638/an-unusual-suspect-causing-hypoxemic-respiratory-failure
#17
Masooma Aqeel, Bjorn Batdorf, Horatiu Olteanu, Jayshil J Patel
Introduction: Antisynthetase syndrome (ASS) is characterized by the presence of anti-Jo-1 antibodies in conjunction with clinical findings of fever, polymyositis-dermatomyositis, and interstitial lung disease (ILD). Inflammatory myopathies carry a high risk of malignancy, but this association is less well outlined in ASS. We present the case of a patient with ASS who developed non-Hodgkin's lymphoma with acute hypoxemic respiratory failure. Case Presentation: A 44-year-old female with ASS presented with acute hypoxemic respiratory failure...
January 2017: Journal of Investigative Medicine High Impact Case Reports
https://www.readbyqxmd.com/read/28209473/analysis-of-peripheral-t-cell-lymphoma-diagnostic-workup-in-the-united-states
#18
Eric D Hsi, Steven M Horwitz, Kenneth R Carson, Lauren C Pinter-Brown, Steven T Rosen, Barbara Pro, Massimo Federico, Christian Gisselbrecht, Marc Schwartz, Lisa A Bellm, Mark Acosta, Angela M Collie, Aaron M Gruver, Bartosz J Grzywacz, Samir Turakhia, Andrei R Shustov, Ranjana H Advani, Tatyana Feldman, Mary Jo Lechowicz, Sonali M Smith, Frederick Lansigan, Anil Tulpule, Michael D Craig, John P Greer, Brad S Kahl, Joseph W Leach, Neil Morganstein, Carla Casulo, Steven I Park, Francine M Foss
BACKGROUND: With increased understanding of the unique entities, subtype-specific approaches for peripheral T-cell lymphoma (PTCL) are emerging, and more precise diagnoses are becoming increasingly important. PATIENTS AND METHODS: We analyzed the approach to the histopathologic diagnosis of PTCL using data from the comprehensive oncology measures of peripheral T-cell lymphoma (COMPLETE) study. The COMPLETE trial is a large prospective cohort study of patients with newly diagnosed PTCL in the United States...
January 10, 2017: Clinical Lymphoma, Myeloma & Leukemia
https://www.readbyqxmd.com/read/28191697/composite-lymphoma-of-peripheral-t-cell-lymphoma-and-hodgkin-lymphoma-mixed-cellularity-type-pathological-and-molecular-analysis
#19
Ayako Ichikawa, Hiroaki Miyoshi, Takuji Yamauchi, Fumiko Arakawa, Riko Kawano, Hiroko Muta, Yasuo Sugita, Koichi Akashi, Koichi Ohshima
Composite lymphomas (CLs) are defined as two unrelated lymphomas occurring at the same time within the same tissue. The incidence of these tumors is low. Of all possible combinations between lymphomas, the least frequent are the ones combining peripheral T-cell lymphoma (PTCL) and Hodgkin lymphoma (HL). We recently identified five cases of CL composed of PTCL and classical HL, mixed cellularity type. We investigated histological and clinical features of these cases. Immunostaining was performed on paraffin sections...
April 2017: Pathology International
https://www.readbyqxmd.com/read/28188140/angioimmunoblastic-t-cell-lymphoma-with-polyarthritis-resembling-rheumatoid-arthritis
#20
Ralph Yachoui, Nouman Farooq, Jonathan V Amos, Gene R Shaw
Angioimmunoblastic T-cell lymphoma (AITL) is a rare subtype of peripheral T-cell lymphoma (PTCL). AITL typically presents with lymphadenopathy, fever, rash, hepatosplenomegaly, and rarely polyarthritis. We report the case of a 50-year-old female who presented with lymphadenopathy, rash, and symmetric polyarthritis. She was later diagnosed with AITL and was treated with chemotherapy with resolution of arthritis. AITL should be suspected in paitents presenting with rheumatoid-like arthritis and diffuse lymphadenopathy...
December 2016: Clinical Medicine & Research
keyword
keyword
47694
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"